OptimizeRx : Corporate Presentation

April 2024

Technology Solutions that Inform and Empower the Healthcare Community

Corporate Presentation

Important Cautions Regarding Forward Looking Statements

• This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such Section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision.
• The words 'believe,' 'expect,' 'may,' 'strategy,' 'future,' 'likely,' 'goal,' 'plan,' 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward- looking statements. Examples of forward-looking statements include, among others, statements we make regarding our expectations related to the size of the market in which we operate, the value of our current and future annual contracts, our growth strategies, our competitive advantage, the scalability of our platform, the plans and objectives of management for future operations, and our financial metrics and performance. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations

and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, any synergies and other anticipated benefits of an acquisition or merger may not be realized or may take longer than anticipated to be realized and integration of the businesses may be more expensive or more difficult than expected, including as a result of unexpected factors or

events, competition within the industries in which we operate, the timing, cost and success or failure of new product and service introductions and developments, our ability to attract and retain qualified personnel, maintaining our intellectual

property rights and litigation involving intellectual property rights, legislative, regulatory and economic developments, and the other risks and uncertainties described in our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Forms 10-Q and 8-K. Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward- looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

• This presentation may include certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in the Appendix.

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

At-a-Glance

Leading technology provider for helping patients start and stay on therapy

Corporate Profile

Re-Founded in 2016, OptimizeRx enables engagement between life sciences organizations, physicians and patients

OptimizeRx powers drug maker brand awareness with physicians and patients while driving patient discovery, treatment initiation, affordability and adherence initiatives

Our technology platform coupled with the nation's largest patient point-of-care network connects the majority of U.S. physicians and patients

The Company has grown to ~135 employees across the United States and Croatia

Stock Information

Stock Price	$11.21
(as of 4/4/24)
Shares Outstanding	~18.2M
fully diluted (as of 11/10/24)
Market Cap	~$203.5M
(as of 4/4/24)
Cash, Cash Equivalents1	$13.9M
(as of 12/31/23)
Total Debt2	$38.3M
(as of 12/31/23)

NASDAQ Exchange listed under ticker

(NASDAQ:OPRX)

1. Includes short-term investments

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Our Mission

• At OptimizeRx ― we are building a more informed and empowered healthcare community with a technology platform that helps people start and stay on life-impacting therapies.
• Our Dynamic Audience Activation Platform (DAAP) delivers predictive and privacy-safe marketing solutions, designed to connect life sciences, HCPs, and patients across the most

robust network of personal and clinical platforms.

Play OptimizeRx DAAP Video

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Growth Leaders | Growth Drivers

Will Febbo

Chief Executive Officer

EXPERIENCE

20+

Leading Health Services and

Financial Businesses

Ed Stelmakh

Chief Financial Officer /

Chief Operations Officer

EXPERIENCE

20+

Legal Corporate and

Business Compliance

EXPERIENCE	EXPERIENCE
20+	20+
Senior Financial	Operations, Sales, and
Roles	Growing Partner Networks
	CCH® Tagetik

Steve Silvestro

President

EXPERIENCE

10+

Healthcare Analysis

Business Development

and Investor Relations

Marion Odence-Ford

General Counsel & Chief Compliance Officer

Andrew D'Silva

SVP Corporate Finance

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Technology that Connects the Healthcare Community

+2 MM	+240 MM
HCPs	Patients

HEALTHCARE PROFESSIONALS

• Navigating a complex treatment landscape	+300
EHRs
• Offset limited EHR interoperability

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

PHARMA

• Connect to key customers
• Support brand market performance

High

ROI

90% Top

20 Pharma

+300

Brands

PATIENTS

• Relevant treatment information
• Productive care discussions

Data-DrivenAI-Enabled Platform Achieves Effective and Efficient Marketing Execution

DAAP deals currently have a ~$1.0 million ACV which we expect will increase as we layer on Medicx's direct-to-patient capabilities // Non- DAAP deals are CPM

Micro-

Neighborhood®

Targeting

Dynamic

Weekly

NPI Lists

DIGITAL AUDIO / OOH*

DIRECT MAIL / EMAIL*

CTV / ATV / OTT*

DIGITAL DISPLAY*

SOCIAL*

DIGITAL POC

FIELD FORCE

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Recent Acquisition of Medicx Health Positions OPRX for Significant Growth and Margin Expansion

The combined entity is positioned to provide true omnichannel access for pharma brands to effectively reach potential patients.

• True omnichannel access to patients for pharmaceutical companies
• Powerful AI engine that can provide pharma access to key patients using a wide variety of criteria
• Significant scale and brand footprint in all corners of the pharma manufacturing space

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Driving Brand Demand Through AI-Driven Platform

CLIENT GOAL

A brand sought to increase awareness among physicians treating newly diagnosed and relapsing rare disease patients.

CLIENT CHALLENGES

• Creating awareness among physicians likely to see patient population earlier in the patient journey-immediately after diagnosis.
• Reaching physicians when already diagnosed patients were showing signs and symptoms of relapse and in need of brand to improve quality of life.

RESULTS

Within a five-month initial program, OptimizeRx generated:

16%	50	9%
of exposed	NEW HIGH-VALUE	DEMAND LIFT per
HCPs writing BRAND	SCRIPTS, increasing	HCP of physicians
PRESCRIPTIONS	incremental brand	exposed to the
	demand	program

HOW WE DID IT

Delivered real-time therapeutic support messaging and banner messaging within the EHR to create brand awareness among HCPs in the electronic workflow during the patient encounter. HCPs identified by OptimizeRx's real-world data (RWD) approach to physician identification had a higher rate of new starts.

EHR WORKFLOW ENGAGEMENT

Delivered brand information directly in the EHR, while HCPs were actively making care decisions.

PATENT-PENDING AI APPROACH

Increased new script writers to the brand by raising awareness among target physicians outside of the brand's physician list.

CARE JOURNEY

Introducing brand messaging to the physician at the right time during the patient journey when the brand would be most

impactful for the patient. Escalate early awareness for early treatment recommendation.

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.

Increasing Brand Touchpoints and Script Lift with Platform

CLIENT GOAL

Increase the number of oncology brand touchpoints by capitalizing on HCP social media presence.

CLIENT CHALLENGES

• Multi-indicationtherapy needed to keep suitability for numerous diseases top-of-mind.
• Oncologists highly present on social media, but untapped opportunity for brand engagement.

RESULTS

In a three-month pilot, DAAP delivered:

33%	44%	142% 1K+
total SCRIPT LIFT	MORE PHYSICIANS	GREATER SCRIPT	incremental
among HCPs	REACHED due to	IMPACT from	SCRIPTS
receiving both	social activation	combined
EHR+Social		EHR+Social
messages		execution, compared
		to single-tactic
		execution

HOW WE DID IT

DAAP's Message Infusion module reached oncologists at multiple points within their workday in both the EHR and on social media, optimizing the number and frequency of touchpoints in order to boost brand engagement and script volumes.

NPI-MATCHED SOCIAL TARGETING

POINT-OF-CARE ENGAGEMENT

OMNICHANNEL EXECUTION

OptimizeRx.com The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. All right reserved, 2024.